The problem with HR 7071

I write this in my own capacity, I am not speaking on behalf of the ALS Association.

A key provision in HR 7071 (“Accelerating Access to Critical Therapies for ALS Act”) authorizes $450 million over four years to underwrite the costs of early access to experimental therapies. This is not a simple ask.  It raises fundamental questions of principles and priorities for the ALS community, questions that deserve a full and open discussion – one that has not happened yet, but needs to happen now.

The goal of the $450 million request is straightforward. It seeks to solve one of the most frustrating impediments people with ALS face in their attempts to gain early access to therapies still in clinical trial – namely, cost. Pharmaceutical companies running clinical trials on therapies demand very high fees for access to their experimental therapies, if they agree to allow early access at all. Depending on the type of therapy, the expenses for early access can be prohibitively expensive for all but the very wealthiest patients, some reaching as high as $1 million per treatment – and they typically require recurring treatments.  The $450 million request – covering $75 million per year in years one and two, and thereafter $150 million annually in years 3 and 4 – is meant to cover costs of early access for people with ALS.

Several legitimate concerns have been raised about this proposal.

  1. It does not solve the problem it presumably sets out to solve — making early access affordable for all people with ALS. Instead, it would only allow a small fraction of Americans living with ALS to gain early access to experimental therapies. This is the case no matter how one works the math. If the most promising therapy in clinical trial happens to be one which runs close to $1 million per treatment, that would enable only 75 people, out of a US population of 25,000 with ALS, to gain access. That’s 1 in 333 of us – roughly the same odds of being diagnosed with ALS. If the treatments cost less, say $300,000 per round, that would still only cover 250 of us, or 1% of the US population of people with ALS.  Even if the cost of early access fell to as little as $10,000 – a figure some argue might be a reasonable estimate for access to a pill-form therapy in a platform trial —  that would cover 7,500 people with ALS, or less than one-third of us in the US. And such a low-ball estimate only raises another objection – if the cost of early access drops to $10,000 for some experimental therapies, why are we asking taxpayers to cover that when middle class and wealthy households could find a way to cover the costs and poorer households could be assisted by other means? 
  2. It risks creating major rifts within the ALS community. Who will choose what constitutes an eligible “promising therapy” and who decides which people with ALS get covered by the subsidy for early access?  How will the vast majority of people with ALS feel when they learn this massive appropriation of funds provides nothing for them?   Some who follow ALS research closer than I do suggest that the most promising therapies in the pipeline in coming years are those targeting familial ALS. Will that result in most or all of the $450 million covering  the 10% of the ALS population that has familial ALS, and how will the 90% with sporadic ALS react?
  3. Given the very poor track record of ALS phase three clinical trials to date, the odds of early access resulting in meaningful outcomes for the lucky few who get it are slim, making this a very high cost, high risk of failure gambit for a small number of people with ALS.  Of the dozens of ALS therapies that have made it to phase three clinical trials, only two have led to approved therapies, and both have only modest, uneven impact in slowly disease progression. This raises a legitimate cost-benefit question about the fund. Could that $450 million be put to better use than this?
  4. If the ALS community can convince Congress to devote $450 million to our disease, earmarking it for research for a cure would be a far better way to make use of the funding.   The bill stipulates that the $450 million be a separate appropriation from research funding, as a way to deflect criticism that this will divert money away from research. But that is a distinction without a difference. The reality is that interest group pressure that is able to secure this kind of funding for early access could certainly be able to do the same for research for a cure. The authorization for early access reflects a choice we as a community are making – that we prioritize gaining subsidized access to experimental therapies for a few of us, now, over seeking a cure for all. Is that what our community wants?

If our priority to to pursue treatments that stop or reverse ALS as speedily as possible for  all people with ALS, there are good reasons to question whether the $450 million for early access is a good idea, and good reasons to argue instead for lobbying for more money for research for a cure.

You may disagree with parts or all of the analysis I share above, but these are very reasonable questions and concerns, and they are being raised across the ALS community.   Fear of being attacked on social media is preventing some people with ALS from saying this publicly, but make no mistake, they are expressing these concerns in private.

What we need now, and what should have happened well before this bill was introduced, is a full, thoughtful, open discussion and debate in the ALS community about whether this bill in its current form actually reflects our priorities and principles, and if not how we can make calls to modify it to make it stronger and aligned with our principles.


Author: Ken Menkhaus

Professor of Political Science at Davidson College. Specialist on Somalia and the Horn of Africa. Interests include development, statebuilding, informal governance systems, peace and conflict studies, and political Islam. I also teach on philanthropy and the non-profit sector.

One thought on “The problem with HR 7071”

  1. It was alarming to read how $450 million in the H7071 could potentially be distributed. Thank you for helping us in the ALS community understand the issues and need for modification of this bill. I am grateful you have the skills and are in a position to push for public forums and better communication between ALS organizations. Lobbying to use $450 million for research over early access sounds like far more of us would have a chance.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: